KIRKWOOD, J.; DUMMER, R.; HAUSCHILD, A.; SANTINAMI, M.; ATKINSON, V.; SILENI, V.; LARKIN, J.; NYAKAS, M.; HAYDON, A.; DUTRIAUX, C.; SCHACHTER, J.; ROBERT, C.; MORTIER, L.; BANERJEE, H.; HAAS, T.; TAN, M.; LAU, M.; SCHADENDORF, D.; LONG, G.; MANDALA, M. Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 1, p. s2, 2021. DOI: 10.25251/skin.5.supp.2. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/1154. Acesso em: 4 jul. 2024.